From the American Academy of Ophthalmology

This prospective open-label study evaluated the efficacy of bevacizumab in diabetic patients with actively leaking new vessels refractory to panretinal photocoagulation. At one year, fluorescein leakage reduced significantly and visual acuity improved among all 12 patients who completed the study. By week six, no fluorescein leakage was observed (P = 0.0001), while BCVA improved from 0.90 ± 0.11 at baseline to 0.70 ± 0.12 at 48 weeks. Patients received a mean of 2.16 injections. Retina, June 2013